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Implementation of foot thermometry plus
mHealth to prevent diabetic foot ulcers:
study protocol for a randomized
controlled trial
Maria Lazo-Porras1, Antonio Bernabe-Ortiz1,2, Katherine A. Sacksteder3, Robert H. Gilman3,4, German Malaga1,5,
David G. Armstrong6 and J. Jaime Miranda1,5*
Abstract
Background: Diabetic foot neuropathy (DFN) is one of the most important complications of diabetes mellitus; its
early diagnosis and intervention can prevent foot ulcers and the need for amputation. Thermometry, measuring
the temperature of the feet, is a promising emerging modality for diabetic foot ulcer prevention. However,
patient compliance with at-home monitoring is concerning. Delivering messages to remind patients to perform
thermometry and foot care might be helpful to guarantee regular foot monitoring. This trial was designed to
compare the incidence of diabetic foot ulcers (DFUs) between participants who receive thermometry alone and
those who receive thermometry as well as mHealth (SMS and voice messaging) over a year-long study period.
Methods/design: This is an evaluator-blinded, randomized, 12-month trial. Individuals with a diagnosis of type 2
diabetes mellitus, aged between 18–80 years, having a present dorsalis pedis pulse in both feet, are in risk group
2 or 3 using the diabetic foot risk classification system (as specified by the International Working Group on the
Diabetic Foot), have an operating cell phone or a caregiver with an operating cell phone, and have the ability to
provide informed consent will be eligible to participate in the study. Recruitment will be performed in diabetes
outpatient clinics at two Ministry of Health tertiary hospitals in Lima, Peru.
Interventions: participants in both groups will receive education about foot care at the beginning of the study and they
will be provided with a thermometry device (TempStat™). TempStat™ is a tool that captures a thermal image of the feet,
which, depending on the temperature of the feet, shows different colors. In this study, if a participant notes a single
yellow image or variance between one foot and the contralateral foot, they will be prompted to notify a nurse to
evaluate their activity within the previous 2 weeks and make appropriate recommendations. In addition to thermometry,
participants in the intervention arm will receive an mHealth component in the form of SMS and voice messages as
reminders to use the thermometry device, and instructions to promote foot care.
Outcomes: the primary outcome is foot ulceration, evaluated by a trained nurse, occurring at any point during the study.
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Discussion: This study has two principal contributions towards the prevention of DFU. First, the introduction of messages
to promote self-management of diabetes foot care as well as using reminders as a strategy to improve adherence to
daily home-based measurements. Secondly, the implementation of a thermometry-based strategy complemented by
SMS and voice messages in an LMIC setting, with wider implications for scalability.
Trial registration: This study is registered in ClinicalTrials.gov: Identifier NCT02373592.
Keywords: Diabetic neuropathies, Thermometry, Diabetes mellitus, Type 2 ulcer, mHealth
Background
There are an estimated 392 million people worldwide
living with type 2 diabetes mellitus (T2DM), 80 % of
whom live in low- and middle-income countries
(LMICs) [1]. Diabetic foot neuropathy (DFN) is a fre-
quent complication and has enormous impacts on pa-
tients, families, and society. According to information
from the US, 60–70 % of people with diabetes will
develop peripheral neuropathy [2] and, of those, up to
25 % will develop a foot ulcer (DFU), a significant prog-
nostic factor for future foot amputation [3].
While data from Peru is limited, our preliminary study
found a 57 % prevalence of DFN at a National Public
Hospital, 20 % of whom are considered to be high-risk
for developing a DFU due to the presence of deformities
[4]. In addition, the economic burden associated with
DFUs – a mostly preventable condition – is enormous.
Some projections indicate that the cost of treating one
case of DFU with surgical debridement ranged between
US$1,022 and US$1,404 in Peru, which is 200 % of the
average monthly family income in Lima, Peru [5]. To
avoid these preventative and costly complications, neces-
sary strategies including patient education, foot care, and
the promotion of appropriate footwear are needed.
Tools to identify early signs of foot damage or inflam-
mation have the potential to reduce the incidence of foot
ulceration and amputation. Thermometry, for example,
measures superficial skin warmth and is a promising
emerging modality to evaluate and manage early signs and
help to prevent DFUs. In three independent clinical trials,
Lavery and Armstrong found that utilization of thermom-
etry among individuals with diabetes at high-risk of devel-
oping a DFU reduced rates of recurring ulcers four- to
ten-fold [6–8]. Moreover, a systematic review indicated
that the use of temperature monitoring is an effective way
to predict and prevent diabetic foot ulceration [9].
Recently, a novel self-assessment device, TempStat™
(Visual Footcare Technologies, LLC, South Salem, NY,
USA), a plastic panel with two polycarbonate plastic pads,
has become available. The plastic pads are constructed of li-
quid crystalline cholesteric esters that react to skin surface
temperature and change color to reflect temperature [10].
Frykberg et al. showed that TempStat™ can detect “alarm
signs,” represented by a yellow color change, and the results
positively correlate to temperature findings of infrared
thermometer, the “gold standard” of thermometry devices
[11]. As such, the use of TempStat™ is a low-cost, at-home,
and patient-friendly way to prevent the development of
DFUs and other complications such as amputation. The
caveat for any thermometry device, however, is that the pa-
tient is required to adhere to self-assessment to achieve the
observed efficacy; i.e., published results suggest that partici-
pants needed to evaluate their foot temperature on at least
50 % of the days to reduce the risk of foot ulceration [7].
In Peru and many other LMICs, clinical consultations are
very short, lasting on average 10− 15 minutes, which mini-
mizes the time allowed for patient education [12, 13]. In
addition, there are significant barriers in physician-patient
communication [14], and medical treatment adherence is
complicated by poor patient literacy and low socioeconomic
status [15, 16]. The lack of resources for specialized diabetic
follow-up programs leaves patients without knowledge of
their disease process and unable to engage in self-care
decision-making. Because of these problems, we need to
identify ways to facilitate improved patient education and
self-management for prevention of diabetic complications.
mHealth – the use of mobile technology to promote
wellness – can close the gap between patient behaviors
and the healthcare system. The use of Short Message
Service (SMS) for diabetes management was evaluated by
two systematic reviews, noting that patients with T2DM
who received text message interventions showed improve-
ments in Self-Efficacy for Diabetes and Diabetes Social
Support Interview scores [17], and thus could improve
clinically diabetes-related health outcomes [18].
Thermometry and SMS have independently demon-
strated enormous potential to lead to positive diabetes-
related outcomes in high-income countries. To strengthen
these approaches in a LMIC in South America, we
propose to use both modalities to evaluate the efficacy of
a combination of foot thermometry with mHealth re-
minders, using SMS and voice messaging, in reducing the
risk of foot ulceration in Peru.
Methods/design
Objectives
The main objective of this study is to compare the 1-year
incidence of DFU in two arms: the intervention arm,
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receiving thermometry and mHealth reminders; and the
control arm receiving thermometry alone. Our hypothesis
is that subjects receiving SMS and voice messaging re-
minders will have a lower incidence of DFU than subjects
who do not receive reminders. Additionally, we will com-
pare patient compliance with thermometer use in both
arms with a temperature-recording logbook.
Primary specific aim
1. Compare the incidence of DFU during the study
period between those who receive thermometry
alone and those who receive thermometry plus SMS
and voice messaging
Secondary specific aims
1. Compare the compliance of foot thermometer use
between the two study arms
2. Compare the frequency of alarm signs reported to
the study nurse between the two study arms
3. Compare the frequency of alarm signs reported in
the patient’s temperature-recording logbooks
between the two study arms
4. Compare the incidence of DFU according to
pre-specified sub-groups: caregiving status, use
of insoles and/or orthopedic shoes
5. In the intervention-only arm, compare the incidence
of DFU by recipient of the messaging intervention
(patient versus caregivers)
Study design
This is a physician- and evaluator-blinded, 1-year, ran-
domized clinical trial with two parallel groups, and a
1:1 allocation.
Participant recruitment and selection criteria
Recruitment will be performed in the outpatient clinics of
the aforementioned hospitals. Subjects will be eligible if
they have a diagnosis of T2DM, are between 18 and
80 years of age, are in risk group 2 or 3 using the diabetic
foot risk classification system (as specified by the Inter-
national Working Group on the Diabetic Foot) [19–21],
have a present dorsalis pedis pulse in both feet, have an op-
erating cell phone or a caregiver with an operating cell
phone, and have the ability to provide informed consent.
Subjects will not be eligible for enrollment if they have
current foot ulcers, active Charcot osteoarthropathy, severe
peripheral arterial disease, or foot infection (Fig. 1).
Foot evaluation to place subjects into an eligible risk
group will be performed using the diabetic foot risk clas-
sification system [22] as shown in Fig. 1. This evaluation
includes a short questionnaire about previous history of
ulceration and/or partial foot amputation, foot evaluation
to detect deformities such as hallux valgus, rigid toe con-
tractures (such as hammer or claw toes), and prominent
metatarsal heads [19], and neuropathy testing using
the vibration perception threshold and the Semmes-
Weinstein monofilament (SWF) [22].
Fig. 1 Process of screening evaluation. Legend: description of the
inclusion and exclusion criteria of the study and screening process.
IWGDF: International Working Group on the Diabetic Foot
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Baseline data collection
We will record participants’ baseline data through question-
naires during visit 1, 1 week after enrollment (see Fig. 2).
This information will include: (1) demographic evaluation,
(2) socioeconomic evaluation, (3) lifestyles including to-
bacco, physical activity, and alcohol consumption, (4) mental
health, specifically depression, (5) participants’ history of car-
diovascular disease and diabetes, (6) current pharmaco-
logical treatment for diabetes, (7) pattern of use of insoles
and orthopedic shoes, (8) mobile phone literacy, (9) an-
thropometric evaluation, and (10) blood pressure evaluation.
Blood samples, to determine baseline levels of gly-
cated hemoglobin, will be conducted at baseline, and
at 6-month and at 12-month follow-up visits.
Randomization
We will follow the Consolidated Standards of Reporting
Trials (CONSORT) Statement of recommendations for
the reporting of randomized trials [23]. Stratification and
blocking randomization, using hospital site as a single
strata, will be performed to generate a random allocation
sequence. Stratification by recruiting hospital site will be
used to ensure that the numbers of participants are
closely balanced within intervention arms.
Subjects will be randomized to one of the two inter-
vention arms via opaque, sealed envelopes, each bearing
on the outside only the name of the hospital and a code.
The preparation of envelopes will be perform using an
independent researcher. Physicians providing care to
study participants in recruiting sites will be blinded to
the study arm allocation, and randomization will occur
between 1 and 6 days after baseline data collection.
Study nurses will assign study codes to each of the
study participants and, independently, codes will have
been randomly assigned into the intervention arm or the
control group. The study coordinator will be responsible
Fig. 2 Flow chart. Legend: description of the trial. HbA1c: Glycated Hemoglobin SMS: Short Message Service
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for opening the sealed envelopes and informing partici-
pants about their assigned study arm as per the random
list, as well as maintaining concealment. The subjects
will be instructed not to discuss their treatment group
assignment with the blinded evaluator.
Intervention
As with any other complex intervention, we have used
the recently proposed TIDieR –template for intervention
description and replication checklist and guide – recom-
mendations to describe our intervention [24]. Briefly, all
study participants will receive education about foot care
at the beginning of the study and they will all be pro-
vided with a thermometry device (TempStat™, Visual
Footcare Technologies, LLC, South Salem, NY, USA).
Participants in the intervention arm will receive, in
addition to thermometry, an mHealth component as
reminders in the form of SMS and voice messages.
Physical and informational materials
Videos were the chosen mechanism to standardize the
education about foot care at the beginning of the study,
and also to standardize the information about use of the
TempStat™. In order to develop the content of our infor-
mation materials, a communicator initially prepared a
questionnaire to assess preferences about education on
healthy habits through audiovisual media and to assess
preferences related to video format. This was accom-
plished through a small pilot study conducted in
diabetes outpatient clinics, with 30 volunteers, over a
2-week-long period. In parallel, a literature search was
conducted to gather information to explain the etiology
and risk factors for the development of neuropathy and
ulcers, as well as to obtain recommendations for foot care
practices and early signs of ulceration. After these proce-
dures, three guides were prepared, two focused on foot
care and one guide was oriented to provide instructions
on the use of the TempStat™ device. Each of the guides
was then used to generate three videos, all of them pro-
duced by an audiovisual specialist. All videos were vali-
dated by physicians and patients with T2DM. The two
videos about foot care are available at https://youtu.be/
qZm2z5Wbwg0 and https://youtu.be/3o0CkEmWeXk,
and the one on how to use the TempStat™ device is avail-
able at https://youtu.be/KotgANRXoIw.
In addition to the videos, all study participants will be
provided with a TempStat™ foot thermometer device.
They will be instructed to use the device daily and will be
asked to record their measurements in a temperature-
recording logbook to be provided by the study nurse.
Finally, on the mHealth intervention arm only, SMS
and voice messages will be sent to participants. The
design and development process of these messages are
provided as Additional file 1.
Procedures, activities, and processes
Enrollment visit After screening, informed consent will
be obtained from all participants by the study’s nurse;
patients will be enrolled and a video about foot care
will be shown to each participant. All of these proce-
dures occur at the same visit, also known as the pre-
screening and enrollment visit. The two videos about
foot care will be shown to participants during enroll-
ment (see Fig. 2).
Visit 1 One week after enrollment (see Fig. 2), the
TempStat™ will be provided to each participant together
with a video about its use. Participants’ usage of the
TempStat™ will be observed by a study nurse to verify
that they use it adequately. Some alarm signs have been
pre-defined on the TempStat™ and the study nurse will
train participants to detect them. These include: (1) yel-
low spots in any area of any feet for two consecutive
days, (2) different colors in contralateral areas of the feet
for two consecutive days, or (3) a dermal lesion. In any
of these three scenarios, subjects will be instructed to
contact the study nurse by phone or SMS. For the first
two types of alarm signs, the contact nurse will ask
about the presence of any lesions as well as the patient’s
activity in the last 2 weeks. The nurse will also provide
recommendations on how to decrease activity until tem-
peratures normalize. If alarm signs continue for more
than 1 week after the telephone consultation, a face-to-
face evaluation will be requested to assess the patient for
infection and/or a masked injury. If a dermal lesion is
present, participants will be asked to be evaluated
promptly by a nurse blind to the intervention. When a
DFU, the main outcome, has been confirmed, the study
nurse will direct the patients to receive professional spe-
cialty care.
Intervention arm In the intervention arm, which in-
cludes an mHealth component, participants will receive
two reminder messages and six foot-care promotion mes-
sages during the study period. The content of these eight
messages has been developed and validated through both
via SMS and voice messaging (see Additional file 1). Dur-
ing the first 2 weeks of the intervention, daily reminders to
use the TempStat™ will be sent Monday to Friday via both
SMS and voice messaging. Thereafter, for the remaining
50 weeks, patients will only receive two messages per
week: one SMS and one voice message with the content
alternating between reminders to use the TempStat™ de-
vice and promotion of foot care.
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Intervention provider
Each participating site will have two study nurses and
one study coordinator.
Nurses will have between 1 and 5 years of previous
experience in diabetes care and will receive, as part of
this study, a specific 2-day training in foot care, foot
evaluation – vibration perception threshold (VPT), SWF,
and pulse evaluation – as well as a description of the
study procedures.
The study coordinator, an early career physician, will
act as study coordinator and will provide support during
the recruitment process. Study coordinators will have
experience in epidemiological tools and research, and
will be trained in detail in all study procedures.
Modes of delivery of the intervention
Recruitment of participants will be face-to-face. General
education about foot care and the use of the TempStat™
will be delivered by audiovisual methods as previously
described. Participants, under the observation of the
study nurse, will perform a sample exercise using
the TempStat™. After this, participants will then be
asked to repeat the measurements every day at home
and to record their observations in a temperature-
recording logbook.
For the mHealth component, SMS and voice messages
will be delivered to the participant’s or caregiver’s cell
phones through an automated software system. Every
week the system will be evaluated by the study coordin-
ator to verify its functionality. More information about
the software is available in Additional file 2.
Type of locations
Much of the intervention is about self-management of
foot care in diabetes and occurs at home. Yet, the re-
cruitment and enrollment into the study will be con-
ducted at two third-level hospitals located in Lima, the
capital of Peru: Hospital Nacional Cayetano Heredia and
Hospital Nacional Arzobispo Loayza. Each hospital re-
corded over 50,000 outpatient visits of patients with
diabetes in 2011 [25]. Both hospitals provide care for
subjects of low socioeconomic status, much of the hos-
pital care is subsidized through a national healthcare
insurance but out-of-pocket payments for laboratory ser-
vices and medicines are still very significant for this
population [26]. Activities related to this protocol began
in late September 2015 and are expected to continue
through 2017.
When and how much?
After enrollment, participants will visit the clinic
1 week later to receive the TempStat™ device and in-
structions to use it. From that point, participants will
visit the clinic every 2 months until the 12-month visit
as shown in Fig. 2.
For the mHealth, during the first 2 weeks into study,
the intervention arm will receive daily reminders to use
the TempStat™ via both SMS and voice messaging.
Thereafter, for the remaining 50 weeks, patients will only
receive two messages per week: one SMS and one voice
message, with content alternating between reminders to
use TempStat™ and promotion of foot care. All messages
will be delivered at 8 a.m.
Tailoring
Some form of tailoring occurs at the mHealth intervention
arm. All the SMS will include the name of the participant
(“Dear participant’s name, …) on, but not in, the voice
messages. A minimal element of additional tailoring is an-
ticipated to occur with all study participants, both inter-
vention and control arms, during their face-to-face
interactions with the study nurse, who will encourage
them to perform daily home evaluations at the week 1 and
each of the 2-month visits.
The thermometry intervention will be the same to all
study participants and has been adapted from previous
experiences in thermometry use [6–8]. The intervention
has been designed to enhance self-care through a therm-
ometry device to be used by participants themselves or
with help from their caregiver. Each patient will be
instructed at the beginning of the study about foot care
and how to perform the thermometry following a stan-
dardized procedure demonstrated on videos.
Assessment of intervention adherence and fidelity
We plan to perform a process evaluation to evaluate fi-
delity of the intervention. The objective of this evalu-
ation will be to: (1) determine if participants know how
to use the TempStat™, (2) determine if participants re-
ceive SMS and voice messages, (3) determine if partici-
pants understand the messages, and (4) obtain opinions
from the participants about feedback received from the
nurse when they call because of an alarm sign. In
addition, we will interview study nurses to collect their
impressions about difficulties and limitations during the
study period [27].
Periodic assessments
Participants will be encouraged to maintain regular visits
with their treating physician in the outpatient clinic.
Each hospital will follow their standard of care for dia-
betes management without restrictions. Also participants
will be asked to visit the diabetes clinic every 2 months
for a general checkup and lower extremity evaluation by
a nurse evaluator. If the nurse identifies an ulcer or any
diabetic complication in a patient, the patient will receive
conventional hospital treatment. At each 2-month visit,
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participants will: (1) complete a questionnaire about dia-
betes treatment, caregiver presence, and use of insoles
and/or orthopedic shoes, and (2) have their weight and
blood pressure measured. Glycated hemoglobin (HbA1c)
will be measured at 6 and 12 months. In addition, infor-
mation from participants’ temperature-recording logbooks
will be recorded.
Outcome measures
Primary outcome measure
The primary outcome is foot ulceration occurring at any
point during the 12-month study period after ran-
domization. Using the American Diabetes Association
criteria [28, 29], foot ulceration will be defined as any
break in the cutaneous barrier that usually extends
through the full thickness of the dermis. The evaluator,
blind to the intervention allocation, will be a trained
nurse.
There will be two ways of identifying if a patient has
developed foot ulceration: (1) during the bimonthly clin-
ical nurse evaluations, and (2) if an alarm sign has been
noted and prompted the participant to seek clinical
evaluation (see Table 1).
Secondary outcome measures
The following have been pre-defined as secondary
outcomes:
1. Adherence to daily temperature measurement:
based on patient self-report of foot temperature
monitoring through use of daily logbook
2. Report of an alarm sign to the nurse: frequency of
alarms signs reported to the study nurse between
study arms will be compared
3. Report of an alarm sign in the temperature-recording
logbook: frequency of alarms signs reported in the
patient’s logbooks between study arms will be
compared
4. Dose-response analysis of SMS and voice messages:
per protocol analysis
5. Glycated hemoglobin control targets: reduction of
1 % or more of glycated hemoglobin after 1 year of
follow-up
Pre-specified sub-group analyses
In all participants, by (1) caregiving status, and (2) use of
insoles and/or orthopedic shoes.
In the intervention arm only, by type of recipient
(patient versus caregivers) of the messaging intervention.
Sample size
Based on previous randomized trials and reports of ul-
ceration in high-risk patients, we expect that 8.5 % of
subjects in the thermometer plus SMS treatment group
will develop ulcers during the evaluation period and that
30 % of subjects in the thermometer-only group will de-
velop foot ulcers [6, 7]. With a power of 0.9 and an
alpha of 0.05, we require a sample size of 78 subjects in
each group to find an absolute change of 21 %, a reduc-
tion from 30 % to 8.5 %. Anticipating a 10 % dropout
rate, we plan to enroll 86 subjects in each study group.
Statistical analysis
The intention-to-treat principle will be performed com-
paring both study arms. To compare rates of ulceration
between arms, we will perform an unadjusted logistic re-
gression, specifically:
logit P ulcerð Þð Þ ≈β0 þ β1:interventionþ β2:site
where a logit function of the probability (P) of having
ulcer depends on β0, the constant coefficient; β1 that
Table 1 Primary and secondary outcomes
Outcomes Source of data
measure End-point
Ulceration Clinical evaluation by a trained nurse Participant’s report Every 2 months until 12 months
Any time during the 12 months
Adherence to daily temperature measurement Logbook Every 2 months until 12 months
Report of an alarm sign to the nurse Nurse report Every 2 months until 12 months
Report of an alarm sign in the logbook Logbook Every 2 months until 12 months
Dose-response analysis of SMS and voice messages Automated system Every 2 months until 12 months
Glycated hemoglobin Blood sample At 6 and 12 months
Sub-group analyses, in all participants
Caregiving status Participant’s report Every 2 months until 12 months
Use of insoles and/or orthopedic shoes Participant’s report Every 2 months until 12 months
Sub-group analyses, intervention arm only
Type of recipient (patient versus caregivers) Participant’s report Every 2 months until 12 months
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indicates the intervention (1 if the participant is in the
intervention arm, and 0 if otherwise), and β2 that refers
to the coefficient of the study site (hospital).
Ulceration is the binary outcome and the intervention
is the mixed modality application of thermometer use
plus mHealth (SMS and voice messages). These analyses
will include all retained participants, regardless of the
number of visits attended. A finding that the coefficient
is significantly greater than zero signifies that the
mHealth intervention strategy has a significantly positive
impact on the reduction of diabetic foot ulceration rates.
Evaluation of other outcomes will be performed ac-
cording to a pre-defined approach.
Sub-group analysis
We will assess treatment effects for a specific patient
characteristic: (1) caregiving status, assistance provided
to the patient with (a) basic activities of daily living, or
(b) in the identification, prevention, or treatment of dia-
betes or any disability, and (2) use of insoles and/or
orthopedic shoes.
Additional sub-group analyses, in the intervention arm
only: exploration of the primary outcome by the type of
recipient (patient versus caregivers) of the messaging.
Ethical issues
An essential element of this randomized trial, mainly re-
lated to the ethics of the study [30], was the decision to
provide thermometry to all study participants. The re-
searchers considered that the evidence available on the ef-
ficacy of thermometry interventions for the prevention of
foot ulcers [6–8] was sufficient to incorporate it as part of
the standard of care. This decision was made despite the
fact that such practice is not currently available in the
study setting or in many LMICs, thus favoring potential
benefits rather than harms. Designing a randomized trial
where the control group would not receive a thermometry
device would be accompanied by a higher incidence of
DFU in this group, a fact that was deemed not appropriate
or ethical. Therefore, the decision was to standardize the
provision of the thermometry device to all study partici-
pants where the only difference between study arms was
the mHealth component, SMS and voice reminders,
assigned only to one of the study arms.
The study protocol, informed consent templates, and
questionnaires have been reviewed and approved by the
Institutional Review Board at Universidad Peruana
Cayetano Heredia in Lima, Peru. In addition, participat-
ing hospitals in the study will receive the protocol and
consents for approval.
Monitoring, quality control and data management
Standard policies of the Universidad Peruana Cayetano
Heredia for the development and review of the protocol
will be followed, as well as policies related to adher-
ence, safety procedures and information management.
The Trial Steering Committee will be composed of the
study coordinator, co-investigators, principal in-
vestigators and the Institutional Review Board of the
Universidad Peruana Cayetano Heredia, who will pro-
vide trial oversight.
According to our Data Monitoring Plan, we will per-
form quality control at multiple stages, which include:
(1) the use of manuals for data collection, (2) weekly
meetings with study nurses, (3) updates training about
protocol procedures, (4) duplicate data entry to the
database, and (5) the ongoing review of the descriptive
statistics of the trial data by the principal investigators
with quality control review of selected data, looking for
inconsistency, missing data and outliers. The databases
will be encrypted and password-protected to ensure con-
fidentiality. Close cooperation between the study co-
ordinator, the data manager, and other members of
the study team will be established to allow the track-
ing of the progress of the study to solve problems
that arise during implementation and to address
other issues on time.
With regards to data monitoring, given the pragmatic
nature of the intervention, we will not establish an inde-
pendent Data Safety and Monitoring Board (DSMB), as
guidance indicates that a “DSMB is specifically required
for multi-site clinical trials with interventions that entail
risk(s) to participants” [31]. Our study is a phase III
pragmatic clinical trial with a positive balance between
harm-benefits for all the study participants. Data man-
ager and investigators will be responsible for procedures
of data monitoring.
Discussion
This study makes two principal contributions towards
the prevention of DFUs. First, the introduction of using
messages to promote self-management of foot care in
diabetes as well as using reminders as a strategy to im-
prove adherence to daily home-based measurements.
Secondly, the implementation of a thermometry-based
strategy complemented by SMS and voice messages in
an LMIC setting, with wider implications for scalability.
A recent systemic review found that, to date, a few
studies with high-quality evidence show that DFUs can
be prevented by complex interventions. Our proposal
uses thermometry to reduce the incidence of foot ulcers
in high-risk diabetic patients, which is an innovative and
cost-effective preventative approach that promotes self-
care at home to empower patient health-management
with recognition of local cultural and economic limita-
tions to healthcare access. Despite its promising expect-
ation, patient compliance to at-home monitoring is an
expected area of concern.
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To address these concerns, we propose concurrent use
of SMS and voice messages to remind patients to per-
form thermometry and then to assess how messages
impact the progression to foot ulceration. SMS, an
mHealth tool, has been shown to have better health out-
comes for various diseases. A recent systematic review
found that SMS reminders were useful in several clinical
applications: adherence to antiretroviral and tuberculosis
medications, and smoking cessation [32]. Data from
Peru show some patients with chronic disease had diffi-
culties reading SMS [33], thus we decided to additionally
use voice messages to evaluate the impact of these com-
munication strategies in prevention of ulceration of the
diabetic foot.
Thermometry and SMS technologies have both been
shown to have enormous potential in high-income coun-
tries, thus we propose to evaluate their utility in Peru,
while combining the modalities to further enhance their
impact. Our proposed methodology creates an early
warning system for DFUs using few healthcare re-
sources, which is a critical attribute for success in LMIC
settings. We take advantage of the relatively high pene-
tration of mobile phone technology – SMS are free for
receivers, i.e., study participants – and our ability to de-
liver a low-cost thermometry device directly to our most
at-risk patients. These tools have the potential to replace
conventional diabetic care approaches in LMICs and to
provide wide coverage in both urban and rural areas.
We strongly believe that interventions such as the one
proposed in this study may be able to extend “ulcer-free
days” in patients in diabetic foot remission [34–36].
This project is being conducted as part of the The
Global Alliance for Chronic Diseases (GACD) Diabetes
Program, www.gacd.org. The GACD brings together the
world’s largest funders of medical and health research to
fund research on non-communicable diseases, with a
collective investment of over US$100 million, across the
vast and diverse GACD Research Network. The GACD
Diabetes Program is the second of three research initia-
tives, with over US$26 million in funding across 17 pro-
jects in 22 countries. Each research project is conducted
through a unique partnership between investigators
from institutions in high-income countries as well as
LIMCs. The aim is to build a collaborative group of
international researchers who meet annually and partici-
pate in joint working groups. All research teams actively
participate in collaborations on implementation science,
common to the studies, with the ultimate goal of trans-
lating evidence into policy.
We believe the creativity of this protocol offers the
potential to tackle a difficult problem from a unique
angle and, therefore, could have a substantial impact on
DFU prevention not only in Peru but also in much of
the world.
Trial status
At the time of submission, this trial is in the process of
participant recruitment.
Additional files
Additional file 1: Message design and evaluation. (DOCX 12 kb)
Additional file 2: mHealth component. (DOCX 11 kb)
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